Genovis AB (publ.)

OM:GENO Stock Report

Market Cap: SEK 2.0b

Genovis AB (publ.) Past Earnings Performance

Past criteria checks 2/6

Genovis AB (publ.) has been growing earnings at an average annual rate of 34.9%, while the Life Sciences industry saw earnings growing at 28.5% annually. Revenues have been growing at an average rate of 21.5% per year. Genovis AB (publ.)'s return on equity is 12.6%, and it has net margins of 21.4%.

Key information

34.9%

Earnings growth rate

34.6%

EPS growth rate

Life Sciences Industry Growth31.8%
Revenue growth rate21.5%
Return on equity12.6%
Net Margin21.4%
Next Earnings Update14 Feb 2025

Recent past performance updates

Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings

Aug 28
Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Feb 22
We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Recent updates

Is It Time To Consider Buying Genovis AB (publ.) (STO:GENO)?

Feb 01
Is It Time To Consider Buying Genovis AB (publ.) (STO:GENO)?

Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Sep 19
Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings

Aug 28
Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings

Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

Aug 23
Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts

Aug 21
The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Aug 12
Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors

May 31
Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors

This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate

May 09
This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 26
Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Mar 18
Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

Feb 28
What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Feb 22
We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Feb 20
These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Feb 04
Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Oct 06
Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

Jun 22
Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

May 13
What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Dec 22
Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

Nov 14
Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

Jul 08
If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Jun 01
Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%

May 10
Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%

One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically

Feb 10
One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically

Revenue & Expenses Breakdown

How Genovis AB (publ.) makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OM:GENO Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2413128760
30 Jun 2412817760
31 Mar 2412831770
31 Dec 2315962790
30 Sep 2315854780
30 Jun 2315157760
31 Mar 2314242730
31 Dec 2210411680
30 Sep 2211941640
30 Jun 2211236600
31 Mar 2211136570
31 Dec 219425530
30 Sep 217111520
30 Jun 216912510
31 Mar 21659500
31 Dec 20616470
30 Sep 2054-3460
30 Jun 20643430
31 Mar 20606410
31 Dec 196110390
30 Sep 195812360
30 Jun 19435330
31 Mar 19401320
31 Dec 1835-2300
30 Sep 1831-4290
30 Jun 1827-6280
31 Mar 1824-7280
31 Dec 1723-8280
30 Sep 1721-9280
30 Jun 1721-9270
31 Mar 1720-14310
31 Dec 1619-15370
30 Sep 1617-16390
30 Jun 1616-21420
31 Mar 1614-18400
31 Dec 1514-20350
30 Sep 1513-25410
30 Jun 1511-24360
31 Mar 1510-23300
31 Dec 1410-22260
30 Sep 148-20240
30 Jun 1410-17240
31 Mar 1411-16230

Quality Earnings: GENO has high quality earnings.

Growing Profit Margin: GENO's current net profit margins (21.4%) are lower than last year (34.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GENO's earnings have grown significantly by 34.9% per year over the past 5 years.

Accelerating Growth: GENO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GENO had negative earnings growth (-48.7%) over the past year, making it difficult to compare to the Life Sciences industry average (20.4%).

Return on Equity

High ROE: GENO's Return on Equity (12.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/03 04:30
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genovis AB (publ.) is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel AlbinDanske Bank
Simon LarssonDanske Bank
Josefine PerssonNordea Markets